|
Scancell Holdings PLC - Oxford, UK-based pharmaceutical firm - Pretax loss multiplies to £13.8 million in the six months to October 31 from £3.6 million a year prior. R&D expenses rise to £8.0 million from £5.7 million, administrative expenses edge up to £2.5 million from £2.4 million. Bottom line hit by £4.5 million loss relating to revaluation of derivative liability compared to £4.9 million gain a year prior. Cash balances at October 31 are £9.1 million compared to £14.8 million at April 30, 2024. Sees cash runway to the second half of 2026 beyond multiple clinical milestones. Current stock price: 9.45 pence, down 2.2% in London on Thursday 12-month change: down 16% Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
